European Commission Approves New Frontline Indications for Pembrolizumab Plus Chemo in Select GI Cancers

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Related Keywords

,European Union ,European Commission ,Merck Research Laboratories ,Eligibility Criteria ,Pembolizumab ,Keytruda ,Gastric Cancer ,Gastroesophageal Cancer ,Biliary Tract Carcinoma ,Gi Cancers ,Gastrointestinal Cancers ,Keynote 859 Trial ,Keynote 966 Trial ,Merck ,